A

    Akebia Ther (AKBA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.92
    +0.04 (+4.58%)

    Market Cap: $254.60M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(18/40)
    Avg Surprise
    -11.06%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.04
    Range$-0.04 - $-0.04
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.03+25.0%
    60d ago$-0.03+25.0%
    30d ago$-0.03+25.0%
    7d ago$-0.04+0.0%
    Current$-0.04
    Revenue Consensus
    $47M
    Range$43M - $51M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.09
    Range$-0.09 - $-0.09
    1 analysts
    Revenue Consensus
    $50M
    Range$40M - $66M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.09---
    Sep 26EST
    		-$-0.04---
    Jun 26
    Reported Aug 5
    		$-0.02$-0.03+33.33%Beat-174.9%
    Mar 26
    Reported May 7
    		$-0.03$-0.02-50.00%Miss-250.0%
    Dec 25
    Reported Feb 26
    		$-0.05$-0.03-66.67%Miss+50.0%
    Sep 25
    Reported Nov 10
    		$0.00N/A+105.00%Beat+102.0%
    Jun 25
    Reported Aug 7
    		$0.03$-0.02+233.50%Beat+166.8%
    Mar 25
    Reported May 8
    		$0.02$-0.04+150.00%Beat+125.0%
    Dec 24
    Reported Mar 13
    		$-0.10$-0.07-33.33%Miss-3225.0%
    Sep 24
    Reported Nov 7
    		$-0.10$-0.05-100.00%Miss-25.0%
    Jun 24
    Reported Aug 8
    		$-0.04$-0.05+20.00%Beat+33.3%
    Mar 24
    Reported May 9
    		$-0.08$-0.09+11.11%Beat+42.9%
    Dec 23
    Reported Mar 14
    		$0.00N/A+108.00%Beat+108.0%
    Sep 23
    Reported Nov 8
    		$-0.08$-0.08+0.00%Beat+72.4%
    Jun 23
    Reported Aug 25
    		$-0.06$-0.02-200.00%Miss-126.1%
    Mar 23
    Reported May 8
    		$-0.14$-0.15+6.67%Beat+60.0%
    Dec 22
    Reported Mar 9
    		$-0.04N/A+78.95%Beat+90.0%
    Sep 22
    Reported Nov 3
    		$-0.29$-0.12-141.67%Miss+14.7%
    Jun 22
    Reported Aug 4
    		$0.23$-0.33+169.70%Beat+145.1%
    Mar 22
    Reported May 9
    		$-0.35$-0.29-20.69%Miss+22.2%
    Dec 21
    Reported Mar 1
    		$-0.40$-0.33-21.21%Miss+33.3%
    Sep 21
    Reported Nov 4
    		$-0.34$-0.29-17.24%Miss+19.0%
    Jun 21
    Reported Aug 5
    		$-0.51$-0.31-64.52%Miss-15.9%
    Mar 21
    Reported May 10
    		$-0.45$-0.36-25.00%Miss+4.3%
    Dec 20
    Reported Feb 25
    		$-0.60$-0.40-50.00%Miss+24.1%
    Sep 20
    Reported Nov 5
    		$-0.42$-0.24-75.00%Miss+8.7%
    Jun 20
    Reported Aug 10
    		$-0.44$-0.47+6.38%Beat+10.2%
    Mar 20
    Reported May 5
    		$-0.47$-0.60+21.67%Beat+24.2%
    Dec 19
    Reported Mar 10
    		$-0.79$-0.47-68.09%Miss+15.1%
    Sep 19
    Reported Nov 12
    		$-0.46$-0.41-12.20%Miss+0.0%
    Jun 19
    Reported Aug 8
    		$-0.49$-0.35-40.00%Miss+18.3%
    Mar 19
    Reported May 9
    		$-0.62$-0.40-55.00%Miss-29.2%
    Dec 18
    Reported Mar 26
    		$-0.93$-0.38-144.74%Miss-472.0%
    Sep 18
    Reported Nov 8
    		$-0.46$-0.56+17.86%Beat+6.1%
    Jun 18
    Reported Aug 8
    		$-0.60$-0.42-42.86%Miss-13.2%
    Mar 18
    Reported May 9
    		$-0.48$-0.53+9.43%Beat+58.3%
    Dec 17
    Reported Mar 12
    		$0.25$-0.35+171.43%Beat+125.3%
    Sep 17
    Reported Nov 8
    		$-0.49$-0.46-6.52%Miss+49.0%
    Jun 17
    Reported Aug 8
    		$-0.53$-0.92+42.39%Beat-
    Mar 17
    Reported May 9
    		$-1.15$-0.41-180.49%Miss-
    Dec 16
    Reported Mar 6
    		$-0.99$0.77-228.57%Miss-
    Sep 16
    Reported Nov 9
    		$-0.96$-1.14+15.79%Beat-

    Key Metrics

    Valuation
    P/E Ratio-9.38EV/EBITDA64.35x
    Price/FCF6.15xFCF Yield16.25%
    Profitability
    Profit Margin-13.50%Operating Margin-5.46%
    ROE-109.40%ROIC-14.09%
    Financial Health
    Debt/Equity1.98xInterest CoverageN/A
    Current Ratio1.43xQuick Ratio1.35x
    Trading Statistics
    Beta0.23Avg Volume8.07M
    52-Week High$3.2052-Week Low$0.81

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.91
    SMA 20$0.94
    SMA 50$1.14
    SMA 200$1.31
    EMA 10$0.92
    EMA 20$0.97
    EMA 50$1.07
    EMA 200$1.42

    MACD

    Line: -0.07Signal: -0.08Hist: 0.01

    ADX

    ADX: 27.4+DI: 18.3-DI: 30.1

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down60.0
    PSAR$1.05

    Bollinger Bands

    Upper Band$1.20
    Lower Band$0.68
    %B Position5539%(Upper)
    Band Width0.46

    RSI (14-Day)

    Neutral
    42.3

    Momentum Oscillators

    Stoch %K66.0
    Stoch %D67.6
    Williams %R-29.7
    ROC (10d)6.8%
    Momentum0.06
    CCI (20d)-31.1
    MFI (14d)66.3

    Volatility Measures

    ATR (14d)$0.07(7.6%)
    StdDev (20d)0.13
    Hist Vol110.4%(High)

    Volume Flow

    VWAP$0.90
    OBV13.5M
    AD Line-24.5M
    CMF (20d)0.079

    Volume Metrics

    Avg Vol (20d)8.4M
    Vol Ratio1.8x(High)
    VWMA (20d)$0.93

    Pivot Points

    R3$1.00
    R2$0.97
    R1$0.92
    Pivot Point$0.89
    S1$0.85
    S2$0.82
    S3$0.77

    Advanced Oscillators

    TSI-25.11
    Ultimate Osc51.2
    KST-260.13

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$49.13M$53.54M$57.62M$58.77M$62.47M$57.34M$46.50M$37.43M$43.65M$32.61M$56.20M$42.05M
    Cost of Revenue$10.42M$12.29M$12.54M$9.38M$9.92M$7.63M$20.36M$14.16M$17.05M$11.61M$18.67M$18.01M
    Gross Profit$38.70M$41.25M$45.09M$49.38M$52.55M$49.71M$26.13M$23.27M$26.60M$21.00M$37.53M$24.04M
    Operating Expenses$45.03M$45.95M$53.64M$44.93M$38.46M$36.20M$40.44M$35.77M$35.33M$35.94M$36.16M$37.07M
    R&D$14.06M$14.81M$26.65M$14.94M$11.01M$9.75M$11.79M$8.49M$7.65M$9.73M$9.87M$13.33M
    SG&A$28.17M$30.44M$26.09M$29.09M$26.55M$25.74M$27.67M$26.52M$26.92M$25.44M$25.43M$22.71M
    Operating Income$-6,326,000$-4,696,000$-8,553,000$4.45M$14.09M$13.51M$-14,306,000$-12,505,000$-8,725,000$-14,936,000$1.37M$-13,036,000
    Interest Income$-3,071,000$-4,691,000$-4,827,000$-4,748,000$-6,834,000$-7,770,000$-6,877,000$-6,661,000$-2,149,000$-2,498,000$-1,419,000$-1,410,000
    Interest Expense$2.51M$4.23M$2.68M$0$13.84M$7.40M$8.50M$0$0$517,000$761,000$0
    Income Before Tax$-8,838,000$-8,928,000$-11,235,000$1.16M$247,000$6.11M$-22,804,000$-20,039,000$-8,582,000$-17,985,000$612,000$-14,489,000
    Income Tax Expense$70,000$126,000$0$615,000$0$0$0$0$0$0$0$0
    Net Income$-8,908,000$-9,054,000$-12,244,000$540,000$247,000$6.11M$-22,804,000$-20,039,000$-8,582,000$-17,985,000$612,000$-14,489,000
    EBITDA$-5,182,000$-3,909,000$-6,087,000$6.22M$7.40M$14.20M$-6,582,000$-4,004,000$2.98M$-5,595,000$11.44M$-3,672,000
    EBIT$-5,767,000$-4,237,000$-6,408,000$5.90M$7.08M$13.88M$-15,927,000$-13,378,000$-6,433,000$-14,970,000$2.03M$-13,079,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about AKBA

    News

    Nantahala Capital Management LLC Takes Position in Akebia Therapeutics, Inc. $AKBA

    Nantahala Capital Management LLC has acquired 2 million shares of Akebia Therapeutics (NASDAQ:AKBA) worth approximately $2.28 million, representing a 0.72% stake. Other institutional investors like BlackRock Inc., UBS Group AG, and Goldman Sachs Group Inc. have also significantly increased their holdings. Analyst sentiment for Akebia Therapeutics is mixed, with a consensus "Hold" rating and an average price target of $3.75, following the company beating its quarterly earnings estimates with a reported loss of $0.02 per share against an estimated $0.04 loss.

    MarketBeat•8/29/26•
    Neutral

    Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Hold" by Analysts

    Six research firms have given Akebia Therapeutics (NASDAQ:AKBA) an average rating of "Hold", with a consensus 12-month target price of $3.75. Recent analyst reports show mixed sentiment, including upgrades, downgrades, and reiterations of "buy" and "sell" ratings. The company recently reported better-than-expected earnings and revenue for the last quarter.

    MarketBeat•8/18/26•
    Neutral

    Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4

    Piper Sandler has reiterated its Buy rating on Akebia Therapeutics (AKBA.US) and maintained its target price at $4. This indicates continued confidence from the analyst firm in the company's prospects.

    Moomoo•8/17/26•
    Bullish

    Akebia Therapeutics, Inc. $AKBA Shares Sold by Renaissance Technologies LLC

    Renaissance Technologies LLC significantly reduced its stake in Akebia Therapeutics (NASDAQ:AKBA) during the first quarter, selling 1.76 million shares and retaining 1.83 million, now valued at $2.55 million. Despite this, Akebia reported stronger-than-expected quarterly revenues of $49.13 million and a smaller loss per share of $0.02, surpassing analyst estimates. The stock, currently trading near its 52-week low, holds an average "Hold" rating from analysts with a consensus price target of $3.75, while institutional investors collectively own 33.92% of the company.

    MarketBeat•8/10/26•
    Neutral

    HC Wainwright Has Negative Outlook of AKBA FY2026 Earnings

    HC Wainwright has revised its FY2026 earnings estimate for Akebia Therapeutics (NASDAQ:AKBA) to a loss of $0.12 per share, down from a previous estimate of $0.08, while maintaining a "Buy" rating. Despite this negative revision, Akebia recently exceeded expectations in its latest quarterly results, reporting a $0.02-per-share loss against a projected $0.04 loss and higher-than-expected revenue. The stock currently holds a consensus "Hold" rating with a target price of $3.75, trading near its 52-week low.

    MarketBeat•8/10/26•
    Somewhat-Bearish

    Frequently Asked Questions About AKBA

    Does AKBA pay dividends?
    Akebia Ther (AKBA) does not currently pay a regular dividend.
    What is AKBA's market cap?
    Akebia Ther (AKBA) has a market capitalization of $254.60M with a current stock price of $0.92.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In